We realize that with limited samples to conduct research, scientists at academic institutions, biotechnology and pharmaceutical companies are not able to test and accelerate the work necessary to find a cure for every child with Duchenne. To remove this barrier, we have partnered with RUCDR Infinite Biologics and Dr. Tahseen Mozaffar from UC Irvine, to create the CureDuchenne Biobank which will collect minimally invasive blood and skin tissue samples that will be banked and made openly accessible for research.
CureDuchenne is committed to ensure that all patients, regardless of mutation, have their own cell lines available to test potential mutation-specific therapies.
We are pleased to announce that the CureDuchenne Biobank is scheduled to collect samples at additional CureDuchenne events in 2020!
Limited spots are still available for each collection, so please register ahead to make sure you have a spot.
01.18.2020 | Tampa, FL
02.08.2020 | Houston, TX
03.14.2020 | Phoenix, AZ
04.04.2020 | Sacramento, CA
04.18.2020 | San Diego, CA
To learn more and get the most up-to-date Biobank information, please fill out this form
or email Romina Foster-Bonds, Director of Programs at: firstname.lastname@example.org
According to the National Organization for Rare Disorders, only 5% of rare diseases have a treatment approved by the Food and Drug Administration. This is due, in part, to the lack of high quality biospecimens for research.
At CureDuchenne, we are committed to removing any barriers to a cure.
We have launched the CureDuchenne Biobank; a collection of biological material and data from Duchenne patients and immediate relatives, stored in an organized system, that is accessible to all qualified Duchenne researchers.
The UCI Clinical team will be collecting minimally invasive biospecimens from patients with Duchenne and unaffected immediate relatives. We will be scheduling future collections alongside select CureDuchenne events across the country.
Skin tissue samples
Patient cell lines specialized to each child can be used by any researcher to develop customized treatments. This is a critical step in de-risking the preclinical drug development stage.
DNA and serum contribute to genetic and biomarker studies to understanding disease progression, prognosis and response to therapies.
Peripheral blood mononuclear cells support research investigating how to harness the immune response to allow for more effective treatment.